Dual Target Ligands with 4-
Amines
/ chemistry
Animals
Catalepsy
/ chemically induced
Cell Line, Tumor
Cell Proliferation
/ drug effects
HEK293 Cells
Haloperidol
Histamine H3 Antagonists
/ chemistry
Humans
Kinetics
Ligands
Male
Molecular Structure
Monoamine Oxidase
/ metabolism
Monoamine Oxidase Inhibitors
/ chemistry
Parkinson Disease
/ physiopathology
Rats, Wistar
Structure-Activity Relationship
4-tert-butylphenyl derivatives
Parkinson’s disease
antagonists
dual-target ligands
histamine H3 receptor
inhibitors
monoamine oxidase B
neurodegenerative disease
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
12 May 2020
12 May 2020
Historique:
received:
18
04
2020
revised:
07
05
2020
accepted:
09
05
2020
entrez:
16
5
2020
pubmed:
16
5
2020
medline:
23
2
2021
Statut:
epublish
Résumé
Dual target ligands are a promising concept for the treatment of Parkinson's disease (PD). A combination of monoamine oxidase B (MAO B) inhibition with histamine H
Identifiants
pubmed: 32408504
pii: ijms21103411
doi: 10.3390/ijms21103411
pmc: PMC7279487
pii:
doi:
Substances chimiques
Amines
0
Histamine H3 Antagonists
0
Ligands
0
Monoamine Oxidase Inhibitors
0
Monoamine Oxidase
EC 1.4.3.4
Haloperidol
J6292F8L3D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Science Centre, Poland
ID : UMO-2016/23/B/NZ7/02327
Organisme : National Science Centre, Poland
ID : 2019/03/X/NZ7/00180
Organisme : German Research Foundation
ID : DFG INST 208/664-1 FUGG
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
J Neural Transm (Vienna). 2018 Nov;125(11):1735-1749
pubmed: 29417334
Bioorg Med Chem. 2006 May 15;14(10):3522-9
pubmed: 16466921
Chem Biol Drug Des. 2016 Aug;88(2):254-63
pubmed: 26931395
J Med Chem. 2019 Oct 24;62(20):8881-8914
pubmed: 31082225
Bioorg Med Chem Lett. 2019 Oct 1;29(19):126612
pubmed: 31421966
Rev Neurol (Paris). 2020 Jan 9;:
pubmed: 31928746
J Med Chem. 2019 Jan 24;62(2):420-444
pubmed: 30035545
Eur J Neurosci. 2001 Oct;14(8):1287-93
pubmed: 11703457
Bioorg Med Chem. 2016 Jan 15;24(2):53-72
pubmed: 26690914
Eur J Pharmacol. 2011 Mar 11;654(3):200-8
pubmed: 21237145
Neurotox Res. 2020 Feb;37(2):286-297
pubmed: 31732870
Bioorg Med Chem Lett. 2020 Jun 1;30(11):127147
pubmed: 32249114
Methods Biochem Anal. 2005;46:1-265
pubmed: 16350889
Anal Biochem. 1997 Nov 15;253(2):169-74
pubmed: 9367499
Future Med Chem. 2015;7(5):609-29
pubmed: 25921401
Pharmacol Rev. 2015 Jul;67(3):601-55
pubmed: 26084539
Eur J Med Chem. 2018 Mar 25;148:487-497
pubmed: 29477889
Biochem Pharmacol. 1973 Dec 1;22(23):3099-108
pubmed: 4202581
Molecules. 2017 Jul 15;22(7):
pubmed: 28714881
Br J Pharmacol. 2011 Oct;164(4):1357-91
pubmed: 21486284
Bioorg Med Chem. 2019 Apr 1;27(7):1195-1210
pubmed: 30808606
J Med Chem. 2014 Aug 14;57(15):6679-703
pubmed: 24955776
Psychopharmacology (Berl). 1999 May;144(1):20-9
pubmed: 10379620
Angew Chem Int Ed Engl. 2017 Oct 2;56(41):12765-12769
pubmed: 28861918
Bioorg Med Chem Lett. 2018 Dec 15;28(23-24):3596-3600
pubmed: 30404719
CNS Drugs. 2020 Feb;34(2):207-218
pubmed: 31997137